Premium
Administration of fluconazole in children below 1 year of age
Author(s) -
Schwarze R.,
Penk A.,
Pittrow L.
Publication year - 1999
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1046/j.1439-0507.1999.00260.x
Subject(s) - fluconazole , medicine , dosing , pharmacokinetics , volume of distribution , candida infections , pediatrics , antifungal , dermatology
For this review, 78 studies regarding the use of fluconazole in a total of 726 children below 1 year of age were evaluated. The range of fluconazole dosage was 2–50 mg kg −1 day −1 , with 162 days being the maximum duration of treatment. According to current experience, fluconazole seems to be well tolerated and efficacious against systemic candidosis and candidaemia in children below 1 year of age, including neonates and very low‐birthweight infants (VLBWIs). The recommended daily dosage is 6 mg kg −1 . (In Germany, fluconazole is approved for children between 1 and 16 years in cases in which there is no therapeutic alternative for treatment of systemic infections caused by Candida spp. and Cryptococcus neoformans in a dosage of 3–6 mg kg −1 day −1 and for superficial Candida infections in a dosage of 1–2 mg kg −1 day −1 .) In patients with impaired renal function, the daily dose should be reduced in accordance with the guidelines given for adults. In neonates during the first 2 weeks of life, this dosage should be administered only every 72 h. In weeks 2–4 of life, the same dose should be given every 48 h, following which daily dosing is appropriate. This posology is derived from the age‐related pharmacokinetics of fluconazole, with a higher volume of distribution and a prolonged plasma elimination half‐life, especially during the first month of life. Drug monitoring during treatment should be performed to ensure therapeutic plasma concentrations of fluconazole within a range between 4 and 20 μg ml −1 . The benefit of fluconazole should be investigated in prospective studies for treatment of systemic candidosis with administration of higher dosages as well as for early empiric therapy in VLBWIs.